Primary prophylaxis of invasive fungal infections in patients with haematological malignancies: 2017 update of the recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO)
Tóm tắt
Từ khóa
Tài liệu tham khảo
Alexander BD, Johnson MD, Pfeiffer CD et al (2013) Increasing echinocandin resistance in Candida Glabrata: clinical failure correlates with presence of FKS mutations and elevated minimum inhibitory concentrations. Clin Infect Dis 56:1724–1732
Annino L, Chierichini A, Anaclerico B et al (2013) Prospective phase II single-center study of the safety of a single very high dose of liposomal amphotericin B for antifungal prophylaxis in patients with acute myeloid leukemia. Antimicrob Agents Chemother 57:2596–2602
Anonymous (2010) Requirements for hygiene in the medical care of immunocompromised patients. Recommendations from the Committee for Hospital Hygiene and Infection Prevention at the Robert Koch institute (RKI). Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz 53:357–388
Ashbee HR, Barnes RA, Johnson EM et al (2014) Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical Mycology. J Antimicrob Chemother 69:1162–1176
Bertz H, Drognitz K, Lubbert M (2014) No difference between posaconazole and fluconazole antifungal prophylaxis and mycological diagnostics except costs in patients undergoing AML chemotherapy: a 1-year "real-life" evaluation. Ann Hematol 93:165–167
Brahmer JR, Tykodi SS, Chow LQ et al (2012) Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 366:2455–2465
Bruggemann RJ, Blijlevens NM, Burger DM et al (2010) Pharmacokinetics and safety of 14 days intravenous voriconazole in allogeneic haematopoietic stem cell transplant recipients. J Antimicrob Chemother 65:107–113
Camps SM, Van Der Linden JW, Li Y et al (2012) Rapid induction of multiple resistance mechanisms in aspergillus fumigatus during azole therapy: a case study and review of the literature. Antimicrob Agents Chemother 56:10–16
Castanheira M, Woosley LN, Diekema DJ et al (2010) Low prevalence of fks1 hot spot 1 mutations in a worldwide collection of Candida strains. Antimicrob Agents Chemother 54:2655–2659
Chau MM, Kong DC, Van Hal SJ et al (2014) Consensus guidelines for optimising antifungal drug delivery and monitoring to avoid toxicity and improve outcomes in patients with haematological malignancy, 2014. Intern Med J 44:1364–1388
Chong GL, Broekman F, Polinder S et al (2015) Aerosolised liposomal amphotericin B to prevent aspergillosis in acute myeloid leukaemia: efficacy and cost effectiveness in real-life. Int J Antimicrob Agents 46:82–87
Coiffier B, Lepage E, Brière J et al (2002) CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346:235–242
Cornely OA, Arikan-Akdagli S, Dannaoui E et al (2014) ESCMID† and ECMM‡ joint clinical guidelines for the diagnosis and management of mucormycosis 2013. Clin Microbiol Infect 20:5–26
Cornely OA, Bohme A, Buchheidt D et al (2009) Primary prophylaxis of invasive fungal infections in patients with hematologic malignancies. Recommendations of the Infectious Diseases Working Party of the German Society for Haematology and Oncology. Haematologica 94:113–122
Cornely OA, Bohme A, Schmitt-Hoffmann A et al (2015) Safety and pharmacokinetics of isavuconazole as antifungal prophylaxis in acute myeloid leukemia patients with neutropenia: results of a phase 2, dose escalation study. Antimicrob Agents Chemother 59:2078–2085
Cornely OA, Cuenca-Estrella M, Meis JF et al (2014) European Society of Clinical Microbiology and Infectious Diseases (ESCMID) fungal infection study group (EFISG) and European Confederation of Medical Mycology (ECMM) 2013 joint guidelines on diagnosis and management of rare and emerging fungal diseases. Clin Microbiol Infect 20:1–4
Cornely OA, Duarte RF, Haider S et al (2016) Phase 3 pharmacokinetics and safety study of a posaconazole tablet formulation in patients at risk for invasive fungal disease. J Antimicrob Chemother 71:718–726
CornelyOA, LeguayT, MaertensJet al. (2017) Randomized comparison of liposomal amphotericin B versus placebo to prevent invasive mycoses in acute lymphoblastic leukaemia. J Antimicrob Chemother
Cornely OA, Leguay T, Maertens J et al (2017) Randomized comparison of liposomal amphotericin B versus placebo to prevent invasive mycoses in acute lymphoblastic leukaemia. J Antimicrob Chemother 72:2359–2367
Cornely OA, Maertens J, Bresnik M et al (2007) Liposomal amphotericin B as initial therapy for invasive mold infection: arandomized trial comparing a high–loading dose regimen with standard dosing (AmBiLoad trial). Clin Infect Dis 44:1289–1297
Cornely OA, Maertens J, Winston DJ et al (2007) Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 356:348–359
Cornely OA, Ullmann AJ (2011) Lack of evidence for exposure-response relationship in the use of posaconazole as prophylaxis against invasive fungal infections. Clin Pharmacol Ther 89:351–352
Courtney R, Wexler D, Radwanski E et al (2004) Effect of food on the relative bioavailability of two oral formulations of posaconazole in healthy adults. Br J Clin Pharmacol 57:218–222
Demille D, Deming P, Lupinacci P et al (2006) The effect of the neutropenic diet in the outpatient setting: a pilot study. Oncol Nurs Forum 33:337–343
Denning DW, Ribaud P, Milpied N et al (2002) Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis 34:563–571
Duarte RF, Lopez-Jimenez J, Cornely OA et al (2014) Phase 1b study of new posaconazole tablet for prevention of invasive fungal infections in high-risk patients with neutropenia. Antimicrob Agents Chemother 58:5758–5765
Enoch DA, Yang H, Aliyu SH et al (2017) The changing epidemiology of invasive fungal infections. Methods Mol Biol (Clifton, N.J.) 1508:17–65
Faderl S, Thomas DA, O'brien S et al (2003) Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies. Blood 101:3413–3415
Falantes JF, Calderon C, Marquez-Malaver FJ et al (2014) Patterns of infection in patients with myelodysplastic syndromes and acute myeloid leukemia receiving azacitidine as salvage therapy. Implications for primary antifungal prophylaxis. Clin Lymphoma Myeloma Leuk 14:80–86
Garcia CA, Wu S (2016) Attributable risk of infection to mTOR inhibitors Everolimus and Temsirolimus in the treatment of cancer. Cancer Investig 34:521–530
Garcia MDC, Redelman-Sidi G (2015) Opportunistic infections in patients receiving immunotherapy with CTLA-4, PD-1 and PD-L1 blockers for treatment of metastatic melanoma. Open Forum Infect Dis 2:1214–1214
Gardner A, Mattiuzzi G, Faderl S et al (2008) Randomized comparison of cooked and noncooked diets in patients undergoing remission induction therapy for acute myeloid leukemia. J Clin Oncol 26:5684–5688
Glasmacher A, Hahn C, Molitor E et al (1999) Itraconazole trough concentrations in antifungal prophylaxis with six different dosing regimens using hydroxypropyl-beta-cyclodextrin oral solution or coated-pellet capsules. Mycoses 42:591–600
Gomes MZ, Jiang Y, Mulanovich VE et al (2014) Effectiveness of primary anti-aspergillus prophylaxis during remission induction chemotherapy of acute myeloid leukemia. Antimicrob Agents Chemother 58:2775–2780
Gross BN, Ihorst G, Jung M et al (2013) Posaconazole therapeutic drug monitoring in the real-life setting: a single-center experience and review of the literature. Pharmacotherapy 33:1117–1125
Guinea J, Escribano P, Marcos-Zambrano LJ et al (2016) Therapeutic drug monitoring of voriconazole helps to decrease the percentage of patients with off-target trough serum levels. Med Mycol 54:353–360
Habermann TM, Weller EA, Morrison VA et al (2006) Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol 24:3121–3127
Hachem R, Assaf A, Numan Y et al (2017) Comparing the safety and efficacy of voriconazole versus posaconazole in the prevention of invasive fungal infections in high-risk patients with hematological malignancies. Int J Antimicrob Agents 50:384–388
Hamada Y, Tokimatsu I, Mikamo H et al (2013) Practice guidelines for therapeutic drug monitoring of voriconazole: a consensus review of the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring. J Infect Chemother 19:381–392
Heine A, Brossart P, Wolf D (2013) Ruxolitinib is a potent immunosuppressive compound: is it time for anti-infective prophylaxis? Blood 122:3843–3844
Heine A, Held SE, Daecke SN et al (2013) The JAK-inhibitor ruxolitinib impairs dendritic cell function in vitro and in vivo. Blood 122:1192–1202
Heinz WJ, Buchheidt D, Christopeit M et al (2017) Diagnosis and empirical treatment of fever of unknown origin (FUO) in adult neutropenic patients: guidelines of the infectious diseases working party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO). Ann Hematol 96:1775–1792
Herbrecht R, Denning DW, Patterson TF et al (2002) Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 347:408–415
Howard SJ, Cerar D, Anderson MJ et al (2009) Frequency and evolution of azole resistance in aspergillus fumigatus associated with treatment failure. Emerg Infect Dis 15:1068–1076
Hu R, Jiang X, Wu Y (2013) Prospective trial finds nystatin mouthwash effective prophylaxis for pulmonary invasive fungal infections that originate in the throat of patients with hematologic malignancies. Neoplasma 60:315–321
Hussaini T, Ruping MJ, Farowski F et al (2011) Therapeutic drug monitoring of voriconazole and posaconazole. Pharmacotherapy 31:214–225
Imhof A, Schaer DJ, Schanz U et al (2006) Neurological adverse events to voriconazole: evidence for therapeutic drug monitoring. Swiss Med Wkly 136:739–742
Jang SH, Colangelo PM, Gobburu JV (2010) Exposure-response of posaconazole used for prophylaxis against invasive fungal infections: evaluating the need to adjust doses based on drug concentrations in plasma. Clin Pharmacol Ther 88:115–119
Johnson LB, Kauffman CA (2003) Voriconazole: a new triazole antifungal agent. Clin Infect Dis 36:630–637
Keating MJ, Flinn I, Jain V et al (2002) Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood 99:3554–3561
Keighley CL, Manii P, Larsen SR et al (2017) Clinical effectiveness of itraconazole as antifungal prophylaxis in AML patients undergoing intensive chemotherapy in the modern era. Eur J Clin Microbiol Infect Dis 36:213–217
Koehler P, Hamprecht A, Bader O et al (2017) Epidemiology of invasive aspergillosis and azole resistance in patients with acute leukaemia: the SEPIA study. Int J Antimicrob Agents 49:218–223
Kontoyiannis DP, Marr KA, Park BJ et al (2010) Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: overview of the transplant-associated infection surveillance network (TRANSNET) database. Clin Infect Dis 50:1091–1100
Kruger WH, Zollner B, Kaulfers PM et al (2003) Effective protection of allogeneic stem cell recipients against aspergillosis by HEPA air filtration during a period of construction--a prospective survey. J Hematother Stem Cell Res 12:301–307
Kuse E-R, Chetchotisakd P, Da Cunha CA et al (2007) Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial. Lancet 369:1519–1527
Kyi C, Hellmann MD, Wolchok JD et al (2014) Opportunistic infections in patients treated with immunotherapy for cancer. J Immunother Cancer 2:19
Lafon-DesmursB, MonselG, LeblondVet al.Sequential disseminated aspergillosis and pulmonary tuberculosis in a patient treated by idelalisib for chronic lymphocytic leukemia. Médecine et Maladies Infectieuses
Larkin J, Hodi FS, Wolchok JD (2015) Combined Nivolumab and Ipilimumab or monotherapy in untreated melanoma. N Engl J Med 373:1270–1271
Laverdiere M, Bow EJ, Rotstein C et al (2014) Therapeutic drug monitoring for triazoles: a needs assessment review and recommendations from a Canadian perspective. Can J Infect Dis Med Microbiol 25:327–343
Lin P-C, Hsiao L-T, Poh S-B et al (2007) Higher fungal infection rate in elderly patients (more than 80years old) suffering from diffuse large B cell lymphoma and treated with rituximab plus CHOP. Ann Hematol 86:95–100
Marks DI, Liu Q, Slavin M (2017) Voriconazole for prophylaxis of invasive fungal infections after allogeneic hematopoietic stem cell transplantation. Expert Rev Anti-Infect Ther 15:493–502
Maschmeyer G (2006) The changing epidemiology of invasive fungal infections: new threats. Int J Antimicrob Agents 27(Suppl 1):3–6
Maschmeyer G (2009) The changing face of febrile neutropenia-from monotherapy to moulds to mucositis. Prevention of mould infections. J Antimicrob Chemother 63(Suppl 1):i27–i30
Maschmeyer G, Haas A, Cornely OA (2007) Invasive aspergillosis: epidemiology, diagnosis and management in immunocompromised patients. Drugs 67:1567–1601
Maschmeyer G, Neuburger S, Fritz L et al (2009) A prospective, randomised study on the use of well-fitting masks for prevention of invasive aspergillosis in high-risk patients. Ann Oncol 20:1560–1564
Menegueti MG, Ferreira LR, Silva MF et al (2013) Assessment of microbiological air quality in hemato-oncology units and its relationship with the occurrence of invasive fungal infections: an integrative review. Rev Soc Bras Med Trop 46:391–396
Merkel D, Filanovsky K, Gafter-Gvili A et al (2013) Predicting infections in high-risk patients with myelodysplastic syndrome/acute myeloid leukemia treated with azacitidine: a retrospective multicenter study. Am J Hematol 88:130–134
MoodyKM, BakerRA, SantizoROet al. (2017) A randomized trial of the effectiveness of the neutropenic diet versus food safety guidelines on infection rate in pediatric oncology patients. Pediatric Blood Cancer
Mori Y, Ikeda K, Inomata T et al (2016) Ruxolitinib treatment for GvHD in patients with myelofibrosis. Bone Marrow Transplant 51:1584–1587
Morrison VA (2010) Infectious complications of chronic lymphocytic leukaemia: pathogenesis, spectrum of infection, preventive approaches. Best Pract Res Clin Haematol 23:145–153
Motzer RJ, Escudier B, Oudard S et al (2010) Phase 3 trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors. Cancer 116:4256–4265
Nachbaur D, Angelova O, Orth-Holler D et al (2015) Primary antifungal prophylaxis with micafungin in patients with haematological malignancies: real-life data from a retrospective single-centre observational study. Eur J Haematol 94:258–264
Nedel WL, Kontoyiannis DP, Pasqualotto AC (2009) Aspergillosis in patients treated with monoclonal antibodies. Revista Iberoamericana de Micologia 26:175–183
Neumann S, Krause SW, Maschmeyer G et al (2013) Primary prophylaxis of bacterial infections and pneumocystis jirovecii pneumonia in patients with hematological malignancies and solid tumors. Ann Hematol 92:433–442
Nihtinen A, Anttila VJ, Richardson M et al (2007) The utility of intensified environmental surveillance for pathogenic moulds in a stem cell transplantation ward during construction work to monitor the efficacy of HEPA filtration. Bone Marrow Transplant 40:457–460
Okamoto K, Proia LA, Demarais PL (2016) Disseminated Cryptococcal disease in a patient with chronic lymphocytic leukemia on Ibrutinib. Case Rep Infect Dis 2016:4642831
Pagano L, Caira M, Candoni A et al (2006) The epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM-2004 study. Haematologica 91:1068–1075
Pascual A, Calandra T, Bolay S et al (2008) Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin Infect Dis 46:201–211
Pfaller MA, Castanheira M, Lockhart SR et al (2012) Frequency of decreased susceptibility and resistance to Echinocandins among fluconazole-resistant bloodstream isolates of Candida Glabrata. J Clin Microbiol 50:1199–1203
Pfaller MA, Diekema DJ (2007) Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev 20:133–163
Pomares H, Arnan M, Sanchez-Ortega I et al (2016) Invasive fungal infections in AML/MDS patients treated with azacitidine: a risk worth considering antifungal prophylaxis? Mycoses 59:516–519
Raad I, Hanna H, Osting C et al (2015) Masking of neutropenic patients on transport from hospital rooms is associated with a decrease in nosocomial aspergillosis during construction. Infect Control Hospital Epidemiol 23:41–43
Reinwald M, Boch T, Hofmann WK et al (2015) Risk of infectious complications in Hemato-oncological patients treated with kinase inhibitors. Biomark Insights 10:55–68
Ribera J-M, Ferrer A, Ribera J et al (2015) Profile of blinatumomab and its potential in the treatment of relapsed/refractory acute lymphoblastic leukemia. OncoTargets Therapy 8:1567–1574
Rieger CT, Cornely OA, Hoppe-Tichy T et al (2012) Treatment cost of invasive fungal disease (Ifd) in patients with acute myelogenous leukaemia (Aml) or myelodysplastic syndrome (Mds) in German hospitals. Mycoses 55:514–520
Rijnders BJ, Cornelissen JJ, Slobbe L et al (2008) Aerosolized liposomal amphotericin B for the prevention of invasive pulmonary aspergillosis during prolonged neutropenia: arandomized, placebo-controlled trial. Clin Infect Dis 46:1401–1408
Sarkaria JN, Galanis E, Wu W et al (2010) Combination of temsirolimus (CCI-779) with chemoradiation in newly diagnosed glioblastoma multiforme (GBM) (NCCTG trial N027D) is associated with increased infectious risks. Clin Cancer Res 16:5573–5580
Schelenz S, Hagen F, Rhodes JL et al (2016) First hospital outbreak of the globally emerging Candida Auris in a European hospital. Antimicrob Resist Infect Control 5:35
Schlesinger A, Paul M, Gafter-Gvili A et al (2009) Infection-control interventions for cancer patients after chemotherapy: a systematic review and meta-analysis. Lancet Infect Dis 9:97–107
Schönberg K, Rudolph J, Vonnahme M et al (2015) JAK inhibition impairs NK cell function in myeloproliferative neoplasms. Cancer Res 75:2187–2199
Schrenk KG, Schnetzke U, Stegemann K et al (2015) Efficacy of antifungal prophylaxis with oral suspension posaconazole during induction chemotherapy of acute myeloid leukemia. J Cancer Res Clin Oncol 141:1661–1668
Scodavolpe S, Quaranta S, Lacarelle B et al (2014) Triazole antifungal agents: practice guidelines of therapeutic drug monitoring and perspectives in treatment optimization. Ann Biol Clin 72:391–404
Stott KE, Hope WW (2017) Therapeutic drug monitoring for invasive mould infections and disease: pharmacokinetic and pharmacodynamic considerations. J Antimicrob Chemother 72:i12–i18
Tacke D, Buchheidt D, Karthaus M et al (2014) Primary prophylaxis of invasive fungal infections in patients with haematologic malignancies. 2014 update of the recommendations of the infectious diseases working Party of the German Society for Haematology and oncology. Ann Hematol 93:1449–1456
Tan K, Brayshaw N, Tomaszewski K et al (2006) Investigation of the potential relationships between plasma voriconazole concentrations and visual adverse events or liver function test abnormalities. J Clin Pharmacol 46:235–243
Teng JC, Slavin MA, Teh BW et al (2015) Epidemiology of invasive fungal disease in lymphoproliferative disorders. Haematologica 100:e462–e466
Topalian SL, Hodi FS, Brahmer JR et al (2012) Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366:2443–2454
Tortorano AM, Peman J, Bernhardt H et al (2004) Epidemiology of candidaemia in Europe: results of 28-month European Confederation of Medical Mycology (ECMM) hospital-based surveillance study. Eur J Clin Microbiol Infect Dis 23:317–322
Trifilio S, Ortiz R, Pennick G et al (2005) Voriconazole therapeutic drug monitoring in allogeneic hematopoietic stem cell transplant recipients. Bone Marrow Transplant 35:509–513
Trifilio S, Pennick G, Pi J et al (2007) Monitoring plasma voriconazole levels may be necessary to avoid subtherapeutic levels in hematopoietic stem cell transplant recipients. Cancer 109:1532–1535
Ueda K, Nannya Y, Kumano K et al (2009) Monitoring trough concentration of voriconazole is important to ensure successful antifungal therapy and to avoid hepatic damage in patients with hematological disorders. Int J Hematol 89:592–599
Ullmann AJ, Lipton JH, Vesole DH et al (2007) Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med 356:335–347
Ullmann AJ, Schmidt-Hieber M, Bertz H et al (2016) Infectious diseases in allogeneic haematopoietic stem cell transplantation: prevention and prophylaxis strategy guidelines 2016. Ann Hematol 95:1435–1455
Van Dalen EC, Mank A, Leclercq E et al (2016) Low bacterial diet versus control diet to prevent infection in cancer patients treated with chemotherapy causing episodes of neutropenia. Cochrane Database Syst Rev 4:Cd006247
Van Der Kolk LE, Baars JW, Prins MH et al (2002) Rituximab treatment results in impaired secondary humoral immune responsiveness. Blood 100:2257–2259
Van Tiel FH, Harbers MM, Terporten PHW et al (2007) Normal hospital and low-bacterial diet in patients with cytopenia after intensive chemotherapy for hematological malignancy: a study of safety†. Ann Oncol 18:1080–1084
Verweij PE, Ananda-Rajah M, Andes D et al (2015) International expert opinion on the management of infection caused by azole-resistant aspergillus fumigatus. Drug Resist Updates 21-22:30–40
Voog E, Morschhauser F, Solal-Celigny P (2003) Neutropenia in patients treated with rituximab. N Engl J Med 348:2691–2694 discussion 2691-2694
Weber JS, Kähler KC, Hauschild A (2012) Management of Immune-Related Adverse Events and Kinetics of response with Ipilimumab. J Clin Oncol 30:2691–2697
Wingard JR, Carter SL, Walsh TJ et al (2010) Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation. Blood 116:5111–5118
Wisplinghoff H, Ebbers J, Geurtz L et al (2014) Nosocomial bloodstream infections due to Candida spp. in the USA: species distribution, clinical features and antifungal susceptibilities. Int J Antimicrob Agents 43:78–81
Wysham NG, Sullivan DR, Allada G (2013) An opportunistic infection associated with ruxolitinib, a novel janus kinase 1,2 inhibitor. Chest 143:1478–1479
Xie S, Chen M, Yan B et al (2014) Identification of a role for the PI3K/AKT/mTOR signaling pathway in innate immune cells. PLoS One 9:e94496